DBVT

DBVT

USD

DBV Technologies S.A. American Depositary Shares

$8.530-0.080 (-0.929%)

即時價格

Healthcare
生物科技
法國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$8.610

最高

$9.350

最低

$8.400

交易量

0.01M

公司基本面

市值

239.0M

行業

生物科技

國家

France

交易統計

平均交易量

0.42M

交易所

NCM

貨幣

USD

52週範圍

最低 $0.441當前 $8.530最高 $9.585

相關新聞

GlobeNewswire

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company

查看更多
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Analyst Upgrades

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

查看更多
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'
GlobeNewswire

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial

查看更多
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
GlobeNewswire

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...

Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the

查看更多
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...